Marie Thibault: And then congrats to Martha — to Dr. Rook on her new role. Can you tell us anything about the priorities she’ll be focused on? Any changes, any tweaks happening on the operations side that she’s focused on?
Gerard Michel: I’ll answer for her in this. I don’t know what day it is, but it’s still in the single digits. The — I think that the number one priority is ensuring we have a robust supply chain. There are a lot of components in this product, a lot of single-source vendors. This is something I’m very familiar with as Sandra and David from Vericel, we had actually more single-source suppliers there. And we made — in the background, we made a strong effort to make that supply chain as robust as possible. And I know that company has never had a stock out. They’ve done a great job, and we’re going to make sure the same thing occurs here. So that’s an ongoing priority, but that’s probably one of her first tasks. I think I’ll leave it at that.
Operator: Our next question comes from I-Eh Jen with Laidlaw & Company. Please go ahead.
I-Eh Jen: Congrats on a good start. My first question is that, Gerard, you suggested that there could be $10 million revenue toward the fourth quarter. Could you give us a little bit what make that assumption and some details of that? Then I have a follow-up.
Gerard Michel: Yes. I think if you run through the metrics I gave a little earlier on the call, where we’re ramping 1 per month, 1.5 per month, 2 per month starting in the first quarter getting to the end of the year on average per site, and then the site activation, which I said 10 by midyear, 15, end of the third quarter, 20, but the end of the fourth quarter and then you multiply that by $182.5 price per kit, you’ll find that you’re going to achieve $10 million by the end of the year.
I-Eh Jen: And the follow-up question is that you’ve got so far have 90 macro list have been trained to — and what do you anticipate over the next quarter or 2 that number might be and the impact you think that could have in terms of going forward?
Gerard Michel: Yes. We’re finding that the average site is sending more than 3 people. They’re often doubling up on either an IR or an anesthesiologist or perfusionists, et cetera, when they go. So you wouldn’t divide that 90 by 3, it to 30. It’s roughly 20 sites have spent at least 1 person or have scheduled a training. I actually haven’t thought through how many do I — how many more preceptorships will occur before the end of the year. I think it will probably be at least a similar number. We’re partly through about 20 institutions right now. Some move at a glacial pace, some move very quickly. So when I said before, it takes about 3 months, in reality, some came rolling through in a little under 2 months and some were on month 5 or working with them or service. So — but I think maybe another 90 to 100 preceptorships would probably get us to 20-plus sites — 20 sites by the end of the year.
I-Eh Jen: Maybe just add 1 more question here, which is a little bit again, forward-looking, given that you had estimate 20 sites in place by year-end. What’s the longer-term goal, for example, for next year? What’s the general thought you have?
Gerard Michel: I-En, I honestly don’t know. And I’ll tell you the reason I don’t know is we need to spread out whether or not 20 to 25 sites is adequately handling the patient flow, whether or not we can put in place adequate referral networks to get the patients to those 20 to 25 sites. If it looks like it makes sense to open 35 sites, we’ll do so. We want to be careful that we don’t open sites that are only doing 1 every month or 2 because I don’t think that will lead to — it may not lead to the best patient outcomes if sites are doing that lower volume. So we’ll have to see how things evolve in terms of commercial sites. We might open other sites just for purposes of R&D. I get a slight train for — that does a modest volume so they can do another indication. But again, I think somewhere between 20% at the low end to 35% is the range next year.
Operator: [Operator Instructions] Our next question comes from Sean Lee with H.C. Wainwright. Please go ahead.
Sean Lee: It’s Sean here for RK, and congrats on the positive commercial developments. My first question is on the expected market. So I was wondering with these the first 20 sites, considering there’s some of the largest cancer centers in the U.S., what percentage of the overall market do you expect to cover by the end of this year?
Gerard Michel: Yes, that’s — I think if we count patients, who have 1 or more referrals at those sites to show up once they get a consult with an oncologist, it’s probably over 75%. If we count, who is actively being treated somewhere else at the moment, it’s a lower percentage. But these patients are used to going somewhere for a referral. And I think that I’ll just put the majority of the market, I’ll just leave it at that will be covered by these sites because we will be actively putting in place referral networks to these sites, expanding upon the referral networks they currently have.